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Alzheimer’s disease (AD) is the leading cause of dementia and represents a significant burden on the global economy and society.
The role of transition metals, in particular copper (Cu), in AD has become of significant interest due to the dyshomeostasis of
these essential elements, which can impart profound effects on cell viability and neuronal function. We tested the hypothesis that
there is a systemic perturbation in Cu compartmentalization in AD, within the brain as well as in the periphery, specifically within
erythrocytes. Our results showed that the previously reported decrease in Cu within the human frontal cortex was confined to the
soluble (𝑃 < 0.05) and total homogenate (𝑃 < 0.05) fractions. No differences were observed in Cu concentration in erythrocytes.
Our data indicate that there is a brain specific alteration in Cu levels in AD localized to the soluble extracted material, which is not
reflected in erythrocytes. Further studies usingmetalloproteomics approaches will be able to elucidate themetabolic mechanism(s)
that results in the decreased brain Cu levels during the progression of AD.
1. Introduction
Alzheimer’s disease (AD) is the predominant cause of demen-
tia in the aging population and represents a mounting health
epidemic [1]. Despite advances in understanding the events
leading to the onset of cognitive decline, the principal cause
of AD is still undetermined. The role of copper (Cu), iron
(Fe), and zinc (Zn) in AD has become of significant interest
because the dyshomeostasis of essential trace elements has
been observed to have profound effects on cell viability
and neuronal function [2, 3], which have been previously
reviewed [4].
Cu, an essential element in the central nervous system
(CNS), is crucial for life, but its unique redox propensity
renders it toxic in circumstances of an increase pool of
labile species [5–8]. Specific lesions in the Cu pathway
can lead to a severe but treatable neurological impairment,
including Menkes and Wilson’s disease [9–11]. Cu displays
a distinctly compartmentalized distribution throughout the
brain, reflecting its diverse function in various neurological
processes [12, 13].
Within the CNS, Cu is known to decrease in the frontal,
occipital, and parietal lobes [14] amygdala and hippocampus
inAD [15].Theprocess for this decline is notwell understood,
though extracellular plaques of aggregated amyloid-𝛽 (A𝛽)
are reported to be enriched with trace elements including Fe,
Zn, and Cu [16]. Recently, it was also reported that frontal
cortex from AD subjects had an increased propensity to bind
exchangeable Cu, which correlated with oxidative damage
observed in the tissue [17].
In cerebral spinal fluid (CSF), Cu levels are not observed
at significantly different concentrations between AD and
healthy controls (HC) [18–20]. However, within peripheral
fluids, Cu dyshomeostasis has been more intensely studied.
2 International Journal of Alzheimer’s Disease
Reports of increased [19, 21], decreased [22, 23], or unchanged
[24–26] serum or plasma Cu in AD have rendered total Cu
levels too variable to be of diagnostic utility, for review see
[27]. Yet, many studies have concluded that there is a subtle
but consistent excess of nonbound or diffusible Cu in serum
[21, 22, 28–34].Despite this, a consensus has been thwarted by
a lack of standardization and limitations driven by covariate
influences on peripheral “high throughout” screening of
Cu concentrations [35]. In other peripheral tissues, such
as erythrocytes, superoxide dismutase 1 (SOD1) activity has
been found to be diminished in AD [23].This is thought to be
due to a Cu deficiency in the enzyme, as reported previously
[36].
In this study, we tested the hypothesis that there is a
systemic perturbation in Cu compartmentalization in AD,
within the frontal cortex as well as in the periphery, within
erythrocytes.
2. Methods
2.1. Subjects. The AIBL study incorporates longitudinal neu-
roimaging, biomarker, neuropsychometric, and lifestyle data,
see [37] for a detailed description of methods. Briefly, par-
ticipants over the age of 65 years and fluent in English were
divided into three groups; cognitively healthy individuals
(HC), participants with mild cognitive impairment (MCI)
based on the established criteria [38, 39], and participants
diagnosed with possible or probable AD as defined by
NINCDS-ADRDA criteria [40]. Written informed consent
was obtained from all participants, and the study was
approved by the appropriate institutional ethics commit-
tees.
2.2. Erythrocyte Preparation. Whole blood was collected
from overnight fasted participants with a 27 g needle,
into Sarstedt S-Monovette Lithium-Heparin 7.5mL tubes
(01.1608.100). The tubes were spun at 3,200×g for 30min
at room temperature, and the plasma was carefully taken
off the hematocrit. The buffy coat was prepared by ficoll
gradient centrifugation to extract the white blood cells. The
erythrocytefraction was washed 3 times by adding 0.9%
normal saline to an end volume of approximately 14mL.
Erythrocytes were dispersed by gently inverting the tubes
10 times and then centrifuged at 650×g for 10 minutes at
20∘C with braking on. The final centrifugation was 1,500×g
for 10 minutes at 20∘C with braking on. The final saline
wash was discarded, and the erythrocytes resuspended to
an end volume of 6mL in phosphate buffered saline (PBS)
(pH 7.4), then aliquoted into polypropylene (Nunc cry-
obank, Denmark) tubes and snap-frozen in liquid nitro-
gen.
2.3. Fractionation of Brain Tissue for Biochemical Analysis.
Brain tissues were obtained from the Victorian brain bank
network, and all experiments were approved by the Uni-
versity of Melbourne health sciences, human ethics sub-
committee (ID1136882). Hemisected frozen brains at −80∘C
were thawed to −20∘C and sectioned in 1 cm slices. The
meninges were removed from approximately 5 g of frontal
cortex (Brodmann area 9), and the grey matter was dis-
sected in to 0.2–0.5 g aliquots and stored at −80∘C. The
grey matter was allowed to thaw on ice and then homoge-
nized using a BioMasher (Omni International). Tissue was
placed in the BioMasher, the plunger was inserted, and
then the apparatus was centrifuged at 100,000×g with a
desktop centrifuge. After centrifugation, Tris buffered saline
(TBS, 50mM Tris pH 8.0, 150mM NaCl) containing EDTA
free protease inhibitors (Roche, 05056489001) was added
at a ratio of 1 : 4 (tissue : buffer, w/v). The sample was
then transferred to ultracentrifuge tubes and centrifuged
at 100,000×g for 30 minutes at 4∘C. The TBS supernatant,
or “soluble” material, was collected and stored at −80∘C
before Western blot analysis. The pellet was resuspended
in 100mM NaCO
3
pH 11.0 (1 : 4, tissue:buffer) and fur-
ther centrifuged at 100,000×g for 30 minutes at 4∘C. The
supernatant, “peripheral membrane/vesicular” material was
recovered, and the pellet was resuspended with 7M urea, 2M
thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 30mM Bicine pH 8.5, and cen-
trifuged at 100,000×g for 30minutes at 4∘C.The supernatant,
“membrane” material, was recovered, and the resulting pellet
was then incubated at room temperature with 70% formic
acid for 16–18 hours before being centrifuged at 100,000×g
for 30 minutes. After the sequential extraction, little to no
observable material remained.
2.4. Induction Coupled Plasma-Mass Spectrometry (ICP-MS).
Frozen aliquots of erythrocytes or brain tissue homogenate
fractions were thawed at room temperature. For brain
homogenates, 50𝜇L was diluted (1 : 20) with 950 𝜇L of
1%HNO
3
(v/v). 50𝜇L of washed erythrocytes were digested
in equivalent volumes of concentrated (65%) HNO
3
and
H
2
O
2
(Merck Millipore) at 80∘C for 5 minutes, then diluted
1 : 20 with 1%HNO
3
. Cu concentration was determined
using an Agilent Technologies 7700x ICP-MS system. The
sample introduction system used a Teflon MiraMist paral-
lel path nebulizer (Burgener Research Inc.) and standard
Scott-type double-pass spray chamber (Glass Expansion).
Helium was used as a collision gas. ICP-MS conditions
were replicated from previously reported studies from our
laboratory [35]. The instrument was calibrated using mul-
tielement standards (Accustandard, ICP-MS-2-1, ICP-MS-3,
and ICP-MS-4; total of 44 elements) containing copper
at 0, 5, 10, 50, and 100 ppb with 89Y as the internal
standard for all isotopes of Cu. Interday relative stan-
dard deviations were determined using a quality control
serum (Seronorm) with a certified copper level (84.55𝜇g/L
95%CI 80.35–88.75𝜇g/L) andwere consistently between 2.0–
5.0%.
2.5. Statistical Analysis. Statistical analyses were performed
with Prism version 6.0 (Graphpad Inc). To compare differ-
ences between the groups, a one-way ANOVA Bonferroni’s
multiple comparison test was used. Significant 𝑃 values were
<0.05.
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Table 1: Distribution of Cu in different cellular fractions and total levels from human brain.
Brain fraction Cu (𝜇g/g of wet weight) 𝑃 value
HC AD
Soluble 1.93 ± 0.6 (1.0–3.2) 1.46 ± 0.6 (0.6–3.3) <0.05
Peripheral/vesicular 0.57 ± 0.2 (0.3–0.9) 0.38 ± 0.3 (0.7–1.1) >0.05
Membrane 0.52 ± 0.2 (0.2–1.2) 0.36 ± 0.2 (0.05–0.8) >0.05
Formic acid¶ 0.52 ± 0.2 (0.3–1.0) 0.38 ± 0.2 (0.05–0.7) >0.05
Total homogenate§ 3.33 ± 2.2 (1.5–13) 2.29 ± 1.0 (0.9–4.7) <0.0001
Concentration based on wet weight of tissue, mean ± standard deviation (range).
¶(HC)𝑁 = 20, (AD)𝑁 = 22, §(HC)𝑁 = 24, and (AD)𝑁 = 23. Numbers in brackets are the 95% confidence intervals. 𝑃 values were calculated using one-
way ANOVA Bonferroni multiple comparison post hoc test. (NS: nonsignificant).
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Figure 1: Cu content in human brain. Illustrates a significant
decrease in total Cu in the soluble fraction of the extracted brain tis-
sue. ∗𝑃 < 0.05, ∗∗∗∗𝑃 < 0.0001; one-way ANOVA with Bonferroni’s
multiple comparison post hoc test of log transformed data. Cu is
decreased in AD frontal cortex. Copper is significantly decreased in
the total homogenate and soluble extracted material (𝑃 < 0.05).The
only fraction that had a significant decrease was the soluble fraction
indicating that the decrease in Cu observed in the total homogenate
is localized to changes in the soluble fraction. HC Healthy Control
(clear boxes), AD Alzheimer’s disease (filled boxes).
3. Results
Table 1 and Figure 1 show that changes in Cu within the
human frontal cortex were localized to the soluble frac-
tion. We observed a significant decrease in total Cu levels
consistent with previous studies [14, 15]. To investigate if
the change in Cu was global or localized to a specific
cellular compartment, we fractionated the brain tissue into
four groups: soluble, peripheral membrane, and vesicular
material, integral membrane and formic acid extractable
material that contains predominantly insoluble plaques [41].
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Figure 2: Cu content in human brain expressed as percentage
distribution. The percent distribution of Cu extracted from human
frontal cortex in the brain is conserved in AD and HC (total
pooled). Box and whisker plots show the range, interquartile range,
and median values. No significant difference was observed in the
percentage of Cu in each of the corresponding fractions. Between
50–60% of the total Cu in human brain tissue is extractable in the
soluble phase. No significant difference was observed between HC
(clear boxes) and AD (filled boxes).
We only observed a significant decrease in Cu in the soluble
fraction between AD and HC (Figure 1, 𝑃 < 0.05, one-
way ANOVA Bonferroni’s multiple comparison test). Table 2
shows the demography for the postmortem brain samples.
Although we did observe a decreasing trend for Cu in each,
we found that when Cu is expressed as a percentage of total
Cu for each individual (Figure 2), no significant differences
were observed, suggesting a conservation of Cu equilibrium
that may be homoeostatically regulated. We observed that
50–60% of total tissue Cu content was localized to the soluble
extractable material (Figure 2).
Previous studies have associated AD specific changes in
erythrocytes [42, 43], including changes in the Cu dependent
enzyme Cu, Zn-superoxide dismutase 1 (SOD1) [23]. We
used well-characterized samples from the AIBL study to
investigate the level of Cu in erythrocytes. Table 3 shows
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Figure 3: Cu concentration in human erythrocytes. The total
Cu content of erythrocytes was determined using ICP-MS. No
significant change (𝑃 = 0.53) in the level of Cu in red blood cells
was observed between HC (𝑁 = 40) (clear boxes) and AD (𝑁 = 40)
(filled boxes).
Table 2: Post-mortem subject demography.
AD HC
𝑃 value
(𝑁 = 30) (𝑁 = 27)
Age (years) 78.0 (9.2) 77.0 (7.6) >0.05
Gender females (%) 27 33 >0.05
ApoE𝜀4 carriers (%) 76 15 <0.0001
PMI (hours) 33.9 (22) 38.4 (14.3) >0.05
Values are means (SD) unless noted above as otherwise. 𝑃 values were
calculated using 𝑡-test (two tailed). HC: healthy control, AD: Alzheimer’s
disease, ApoE𝜀4: Apolipoprotein E epsilon 4, PMI: postmortem interval.
the AIBL cohort demographics for individuals analysed for
erythrocyte Cu concentrations. Figure 3 shows that there was
no significant difference in erythrocytic Cu concentration
observed between AD and control samples.
4. Discussion
The aim of this study was to investigate the distribution and
concentration of Cu in the frontal cortex and periphery of
AD subjects when compared to age-matched healthy control
samples. A number of studies have indicated that there is
a significant perturbation in Cu coordination in AD within
the frontal cortex [14, 17, 44] and periphery [3, 27]. Using
well-characterized subjects, we were unable to demonstrate
a significant difference in Cu levels within erythrocytes,
a finding which is consistent with our investigations of
serum Cu levels [35]. However, we did observe a significant
difference within the frontal cortex, where AD tissue had
Table 3: AIBL cohort demographics for individuals analysed for
erythrocyte Cu levels.
HC AD
𝑃 value
(𝑁 = 40) (𝑁 = 40)
Age (years) 76.8 (8.0) 77.3 (8.0) >0.05
Gender females (%) 47.5 55 >0.05
ApoE𝜀4 carriers (%) 37.5 60 <0.05
MMSE 28.4 (1.4) 18.1 (6.0) <0.0001
CDR 0.075 (0.2) 6.175 (3.2) <0.0001
Values are means (SD) unless noted above as otherwise. 𝑃 values were
calculated using one-way ANOVA Bonferroni multiple comparison post
hoc test. HC: healthy control, AD: Alzheimer’s disease, and MMSE: Mini-
Mental State Examination. CDR: clinical dementia rating scale, ApoE𝜀4:
Apolipoprotein E epsilon 4.
significantly less Cu than controls (𝑃 = <0.0001). This obser-
vation is consistent with the frontal cortex having a unique
susceptibility for Cu deficiency, compared to the periphery.
Previous studies have used fractionation to investigate trace
elements in AD brain [45], but data on changes to Cu
concentrations is lacking. By fractionating brain tissue into
several biochemical distinct subunits we observed that the
decrease in Cu is mainly confined to the soluble fraction.
The change in the soluble fraction is consistent with the
reported deficiency of metallothioneins in the AD brain [46],
though further metalloproteomic investigations are required
to determine the extent that the Cu proteome is altered
in AD neuropathology [47]. Surprisingly, no significant
difference was observed in the formic acid fraction (Figure 1),
contrary to our expectation that the AD plaques would
demonstrate increased Cu in line with previous reports [48,
49]. The absence of an increase in Cu in the formic acid
fraction highlights the importance of using spatially resolved
techniques to measure tissue distribution of trace elements,
including X-raymicrofluorescencemicroscopy [50] and laser
ablation ICP-MS [51, 52].
We have shown that over 50% of the Cu in human brain
tissue can be extracted in the soluble or cytosolic portion
of the homogenate. Further, the changes observed in the
AD brain are due to specific changes in this soluble phase.
As Cu has a strong propensity to participate in free radical
chemistry, the distribution and delivery of Cu are carefully
controlled by a set of Cu specific protein machinery [13, 53,
54]. This Cu handling system maintains less than one free
Cu ion per cell [55]. Therefore, essentially all of the Cu is
bound to biological ligands or is chaperoned byCu regulatory
proteins. Future investigations using a metalloproteomic
approach [56–58] will be able to determine if the changes
in the soluble Cu levels are specific to changes in binding
partners, such as the reported decrease in metallothionein
observed in AD [46]. As Cu is tightly regulated and exists as
a ligated entity in the cell, it will be interesting to investigate
if the change in soluble Cu are global, suggesting all Cu-
proteins are decreased in AD, or are the changes restricted
to selective proteins. In particular, detailed investigations of
the stoichiometry of Cu proteins, like ceruloplasmin and
the three reported metallothionein isoforms, will also be
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informative concerning Cu perturbations that may lead to
deficiency in the CNS.
In conclusion, this study has examined two pools of
Cu in AD compared to age matched HCs. We showed that
there is a specific change in the frontal cortex, indicating
there is a perturbation in Cu homeostasis leading to a local
diminution in concentration. We did not detect a significant
difference in erythrocytes, suggesting that Cu disturbance
may be confined to the brain in AD, precluding peripheral
Cu levels as a useful biomarker for AD. The timing, systemic
covariates, and mechanism(s) of this alteration still need
to be systemically investigated, and advanced analytical
metalloproteomic techniques will go a long way to answer
these questions in the future.
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